Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

With FDA nod, Regeneron brings an RNAi drug to autoimmune disease

The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Thursday 19 November →